BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 27510492)

  • 1. Neuronutrient Amino-Acid Therapy Protects Against Reward Deficiency Syndrome: Dopaminergic Key to Homeostasis and Neuroplasticity.
    Blum K; Febo M; Badgaiyan RD; Braverman ER; Dushaj K; Li M; Demetrovics Z
    Curr Pharm Des; 2016; 22(38):5837-5854. PubMed ID: 27510492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurogenetics of dopaminergic receptor supersensitivity in activation of brain reward circuitry and relapse: proposing "deprivation-amplification relapse therapy" (DART).
    Blum K; Chen TJ; Downs BW; Bowirrat A; Waite RL; Braverman ER; Madigan M; Oscar-Berman M; DiNubile N; Stice E; Giordano J; Morse S; Gold M
    Postgrad Med; 2009 Nov; 121(6):176-96. PubMed ID: 19940429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do dopaminergic gene polymorphisms affect mesolimbic reward activation of music listening response? Therapeutic impact on Reward Deficiency Syndrome (RDS).
    Blum K; Chen TJ; Chen AL; Madigan M; Downs BW; Waite RL; Braverman ER; Kerner M; Bowirrat A; Giordano J; Henshaw H; Gold MS
    Med Hypotheses; 2010 Mar; 74(3):513-20. PubMed ID: 19914781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overcoming qEEG abnormalities and reward gene deficits during protracted abstinence in male psychostimulant and polydrug abusers utilizing putative dopamine D₂ agonist therapy: part 2.
    Blum K; Chen TJ; Morse S; Giordano J; Chen AL; Thompson J; Allen C; Smolen A; Lubar J; Stice E; Downs BW; Waite RL; Madigan MA; Kerner M; Fornari F; Braverman ER
    Postgrad Med; 2010 Nov; 122(6):214-26. PubMed ID: 21084796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute intravenous synaptamine complex variant KB220™ "normalizes" neurological dysregulation in patients during protracted abstinence from alcohol and opiates as observed using quantitative electroencephalographic and genetic analysis for reward polymorphisms: part 1, pilot study with 2 case reports.
    Miller DK; Bowirrat A; Manka M; Miller M; Stokes S; Manka D; Allen C; Gant C; Downs BW; Smolen A; Stevens E; Yeldandi S; Blum K
    Postgrad Med; 2010 Nov; 122(6):188-213. PubMed ID: 21084795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation instead of blocking mesolimbic dopaminergic reward circuitry is a preferred modality in the long term treatment of reward deficiency syndrome (RDS): a commentary.
    Blum K; Chen AL; Chen TJ; Braverman ER; Reinking J; Blum SH; Cassel K; Downs BW; Waite RL; Williams L; Prihoda TJ; Kerner MM; Palomo T; Comings DE; Tung H; Rhoades P; Oscar-Berman M
    Theor Biol Med Model; 2008 Nov; 5():24. PubMed ID: 19014506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypothesizing That Neuropharmacological and Neuroimaging Studies of Glutaminergic-Dopaminergic Optimization Complex (KB220Z) Are Associated With "Dopamine Homeostasis" in Reward Deficiency Syndrome (RDS).
    Blum K; Febo M; Fried L; Li M; Dushaj K; Braverman ER; McLaughlin T; Steinberg B; Badgaiyan RD
    Subst Use Misuse; 2017 Mar; 52(4):535-547. PubMed ID: 28033474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Manipulation of catechol-O-methyl-transferase (COMT) activity to influence the attenuation of substance seeking behavior, a subtype of Reward Deficiency Syndrome (RDS), is dependent upon gene polymorphisms: a hypothesis.
    Blum K; Chen TJ; Meshkin B; Waite RL; Downs BW; Blum SH; Mengucci JF; Arcuri V; Braverman ER; Palomo T
    Med Hypotheses; 2007; 69(5):1054-60. PubMed ID: 17467918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine gene predicts the brain's response to dopaminergic drug.
    Cohen MX; Krohn-Grimberghe A; Elger CE; Weber B
    Eur J Neurosci; 2007 Dec; 26(12):3652-60. PubMed ID: 18088284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopamine in the Brain: Hypothesizing Surfeit or Deficit Links to Reward and Addiction.
    Blum K; Thanos PK; Oscar-Berman M; Febo M; Baron D; Badgaiyan RD; Gardner E; Demetrovics Z; Fahlke C; Haberstick BC; Dushaj K; Gold MS
    J Reward Defic Syndr; 2015; 1(3):95-104. PubMed ID: 27398406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Narcotic antagonists in drug dependence: pilot study showing enhancement of compliance with SYN-10, amino-acid precursors and enkephalinase inhibition therapy.
    Chen TJ; Blum K; Payte JT; Schoolfield J; Hopper D; Stanford M; Braverman ER
    Med Hypotheses; 2004; 63(3):538-48. PubMed ID: 15288384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. rsfMRI effects of KB220Z™ on neural pathways in reward circuitry of abstinent genotyped heroin addicts.
    Blum K; Liu Y; Wang W; Wang Y; Zhang Y; Oscar-Berman M; Smolen A; Febo M; Han D; Simpatico T; Cronjé FJ; Demetrovics Z; Gold MS
    Postgrad Med; 2015 Mar; 127(2):232-41. PubMed ID: 25526228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reward deficiency syndrome: genetic aspects of behavioral disorders.
    Comings DE; Blum K
    Prog Brain Res; 2000; 126():325-41. PubMed ID: 11105655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuro-chemical activation of brain reward meso-limbic circuitry is associated with relapse prevention and drug hunger: a hypothesis.
    Blum K; Gold MS
    Med Hypotheses; 2011 Apr; 76(4):576-84. PubMed ID: 21306831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between dopaminergic neurotransmission, alcoholism, and Reward Deficiency syndrome.
    Bowirrat A; Oscar-Berman M
    Am J Med Genet B Neuropsychiatr Genet; 2005 Jan; 132B(1):29-37. PubMed ID: 15457501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coupling Neurogenetics (GARS™) and a Nutrigenomic Based Dopaminergic Agonist to Treat Reward Deficiency Syndrome (RDS): Targeting Polymorphic Reward Genes for Carbohydrate Addiction Algorithms.
    Blum K; Simpatico T; Badgaiyan RD; Demetrovics Z; Fratantonio J; Agan G; Febo M; Gold MS
    J Reward Defic Syndr; 2015; 1(2):75-80. PubMed ID: 27617300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imaging gene-substance interactions: the effect of the DRD2 TaqIA polymorphism and the dopamine agonist bromocriptine on the brain activation during the anticipation of reward.
    Kirsch P; Reuter M; Mier D; Lonsdorf T; Stark R; Gallhofer B; Vaitl D; Hennig J
    Neurosci Lett; 2006 Sep; 405(3):196-201. PubMed ID: 16901644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reward circuitry dopaminergic activation regulates food and drug craving behavior.
    Blum K; Liu Y; Shriner R; Gold MS
    Curr Pharm Des; 2011; 17(12):1158-67. PubMed ID: 21492092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Shared Molecular and Genetic Basis for Food and Drug Addiction: Overcoming Hypodopaminergic Trait/State by Incorporating Dopamine Agonistic Therapy in Psychiatry.
    Gold MS; Badgaiyan RD; Blum K
    Psychiatr Clin North Am; 2015 Sep; 38(3):419-62. PubMed ID: 26300032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pro-Dopamine Regulator - (KB220) to Balance Brain Reward Circuitry in Reward Deficiency Syndrome (RDS).
    Blum K; Febo M; Fried L; Baron D; Braverman ER; Dushaj K; Li M; Demetrovics Z; Badgaiyan RD
    J Reward Defic Syndr Addict Sci; 2017; 3(1):3-13. PubMed ID: 28804788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.